YD Bio (NASDAQ:YDES) Stock Price Down 4.4% – Should You Sell?

Shares of YD Bio Limited (NASDAQ:YDES) dropped 4.4% during trading on Wednesday. The company traded as low as $6.80 and last traded at $7.2760. 68,234 shares traded hands during trading, a decline of 52% from the average session volume of 141,640 shares. The stock had previously closed at $7.61.

Analyst Upgrades and Downgrades

Separately, Wall Street Zen raised YD Bio to a “hold” rating in a research report on Saturday. One analyst has rated the stock with a Sell rating, According to MarketBeat, YD Bio currently has a consensus rating of “Sell”.

YD Bio Stock Down 0.9%

The firm has a fifty day simple moving average of $3.52 and a 200 day simple moving average of $4.16.

YD Bio (NASDAQ:YDES) last announced its quarterly earnings data on Tuesday, September 1st. The biotechnology company reported $0.05 earnings per share for the quarter. The firm had revenue of $0.42 million for the quarter.

Institutional Investors Weigh In On YD Bio

A hedge fund recently raised its position in YD Bio stock. Cypress Capital Management LLC WY raised its holdings in YD Bio Limited (NASDAQ:YDES) by 9.8% during the 2nd quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 33,690 shares of the biotechnology company’s stock after buying an additional 3,000 shares during the quarter. Cypress Capital Management LLC WY’s holdings in YD Bio were worth $76,000 as of its most recent SEC filing.

About YD Bio

YD Bio Limited is a biotechnology company advancing DNA methylation-based cancer detection technology and ophthalmologic innovations.